Table 1. Clinical and pathological characteristics of NSCLC patients diagnosed with BM who received erlotinib plus bevacizumab as initial treatment for BM.

Case	Age (years)/sex	EGFR mutation	PS	Number of BMs	BM size (mm)	BM-related symptoms	Extracerebral portion	History of surgery	History of TKI
1	65/F	L858R	2	2	10	None	OSS	LUL	None
2	71/F	L858R	1	6	8	None	PUL, OSS, pleural	RLL	Gefitinib
3	65/F	Exon 19 deletion	1	6	13	None	LN, OSS	RLL	Gefitinib
4	46/M	Exon 19 deletion	1	≥10	17	Headache	PUL	LLL	None
5	65/M	L858R	0	≥10	9	None	PUL, OSS	None	Gefitinib
6	75/F	L858R	0	≥10	27	None	PUL, LN	None	None
7	60/F	Exon 19 deletion	2	7	17	Headache	PUL, OSS, ADR, LN	None	None
8	74/F	Exon 19 deletion	0	6	11	None	PUL, LN, OSS	RLL	None

NSCLC, non-small cell lung cancer; PS, performance status; BM, brain metastasis; TKI, tyrosine kinase inhibitor; OSS, ossa; PUL, pulmonary; LN, lymph node; ADR, adrenal; LUL, left upper lobectomy; RLL, right lower lobectomy; LLL, left lower lobectomy.